NR5A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL46200	1.00	17/20
SCHEMBL25777	0.83	2/20
SCHEMBL233018	0.83	2/20
SCHEMBL234615	0.83	2/20
SCHEMBL79578	0.82	2/20
SCHEMBL236438	0.82	2/20
SCHEMBL235399	0.78	2/20
SCHEMBL235516	0.74	2/20
SCHEMBL160176	0.63	2/20
Trifluoromethanesulfonic Acid (SCHEMBL184536)	0.57	2/20
SCHEMBL3580	0.34	2/20
SCHEMBL10827	0.34	2/20
SCHEMBL14599	0.34	2/20
SCHEMBL3214	0.31	2/20
SCHEMBL24563	1.00	1/20
Colfosceril Palmitate (SCHEMBL24980)	1.00	1/20
Dimyristoylphosphatidylcholine (SCHEMBL37475)	1.00	1/20
SCHEMBL44308	1.00	1/20
SCHEMBL57745	1.00	1/20
SCHEMBL79239	1.00	1/20

Clinical trials — most relevant to NR5A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills	PHASE4	COMPLETED
Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism	PHASE4	COMPLETED
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment	PHASE4	RECRUITING
Effects of Tibolone Treatment on the Endometrium	PHASE4	COMPLETED
Androgen for Leydig Cell Proliferation	PHASE2/PHASE3	COMPLETED
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents	PHASE3	WITHDRAWN
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)	PHASE3	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy	PHASE2	NOT_YET_RECRUITING
AMG 386 and Abiraterone for Advanced Prostate Cancer	PHASE2	COMPLETED
Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer	PHASE2	COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
Androgen Reduction in Congenital Adrenal Hyperplasia	PHASE2	WITHDRAWN
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	PHASE1	COMPLETED
Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)	nan	RECRUITING
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
Early Mental Response - The EMRE Study	nan	RECRUITING
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation	nan	UNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency	nan	COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Study of Adrenal Gland Tumors	nan	COMPLETED
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?	nan	UNKNOWN
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN
Influence of External Factors on Skeletal Growth in Youth	nan	ACTIVE_NOT_RECRUITING
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NR5A1 binder may also engage these)

Protein	Name	Similarity
Q9GKL2	—	1.000	Q9GKL2 →
P50569	—	1.000	P50569 →
Q95L87	—	1.000	Q95L87 →
P33242	—	1.000	P33242 →
P79387	—	1.000	P79387 →
Q04752	—	1.000	Q04752 →
Q64249	—	0.998	Q64249 →
NR1H2	Oxysterols receptor LXR-beta	0.998	landscape →
P28700	—	0.998	P28700 →
Q6QMY5	—	0.997	Q6QMY5 →
Q5QJV7	—	0.997	Q5QJV7 →
NR4A3	Nuclear receptor subfamily 4 group A member 3	0.997	landscape →
Q0ZAQ8	—	0.997	Q0ZAQ8 →
ESRRB	Steroid hormone receptor ERR2	0.996	landscape →
RXRB	Retinoic acid receptor RXR-beta	0.996	landscape →
P45448	—	0.996	P45448 →
F1QLY4	—	0.996	F1QLY4 →
NR4A1	Nuclear receptor subfamily 4immunitygroup A member 1	0.996	landscape →
RXRA	Retinoic acid receptor RXR-alpha	0.995	landscape →
P51128	—	0.995	P51128 →
P49870	—	0.995	P49870 →
P49867	—	0.995	P49867 →
P51448	—	0.995	P51448 →
Q9QZB6	—	0.994	Q9QZB6 →
Q9TTR8	—	0.994	Q9TTR8 →
Q06725	—	0.994	Q06725 →
NR5A2	Nuclear receptor subfamily 5 group A member 2	0.994	landscape →
P12813	—	0.994	P12813 →
Q9QWM1	—	0.994	Q9QWM1 →
Q15406	—	0.994	Q15406 →